- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05819476
Boosting Open-Label Placebo Effects in Acute Induced Pain in Healthy Adults (BOLPAP)
This study is to investigate the effect of open-label placebo (OLP) application on acute pain in an experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
In Part 1 duration of OLP analgesia will be examined, and onset and size of the effect will be reevaluated.
In Part 2 of this study outcomes between subjects receiving one OLP injection, subjects receiving one repetition of the injection on a fixed time point and subjects receiving one repetition of the injection on-demand will be evaluated
Study Overview
Status
Conditions
Detailed Description
Pain is highly prevalent in hospital settings. Standard systemic treatment for acute pain consists mainly of basic analgesia. The use of these drugs is often restricted due to their contraindications. Placebo is used nowadays to describe sham treatments and "inert" substances like sugar pills and saline injections. Placebos are proven to elicit clinically significant effects in various conditions, including pain. Ethical concerns about the use of deceptive placebos have prevented their implementation in clinical practice. A possibility to address this issue would be to prescribe placebos openly, that means, without deception. This randomized crossover study evaluates the efficacy of open-label placebo (OLP) in acute pain. Subjective pain ratings and areas of hyperalgesia and allodynia will be measured in a well-established experimental pain model (intradermal electrical stimulation model evoking pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment) and analgesia elicited by OLP injections will be investigated.
In Part 1 duration of OLP analgesia will be examined, and onset and size of the effect will be reevaluated.
In Part 2 of this study outcomes between subjects receiving one OLP injection, subjects receiving one repetition of the injection on a fixed time point and subjects receiving one repetition of the injection on-demand will be evaluated (which leaves the last group a choice over when they would like to have the placebo "booster").
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tobias Schneider, MD
- Phone Number: +41 61 328 65 43
- Email: tobias.schneider@usb.ch
Study Contact Backup
- Name: Jan Vognstrup
- Phone Number: +41 61 328 65 42
- Email: jan.vognstrup@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital of Basel (USB); Department of Anaesthesiology
-
Contact:
- Tobias Schneider, MD
- Phone Number: +41 61 328 65 43
- Email: tobias.schneider@usb.ch
-
Principal Investigator:
- Tobias Schneider, MD
-
Sub-Investigator:
- Jens Gaab, Prof.
-
Sub-Investigator:
- Matthijs de Leeuw
-
Sub-Investigator:
- Flavia Flepp
-
Contact:
- Jan Vognstrup
- Phone Number: +41 61 328 65 42
- Email: jan.vognstrup@usb.ch
-
Sub-Investigator:
- Jan Vognstrup
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy volunteers (ASA Class I or II), aged 18 to 65 years
- BMI between 18 and 25kg/m2
- Able to understand the study and the NRS
- Able to give informed consent
Exclusion Criteria:
- Participation in a previous open-label placebo study; for Part 2, this includes Part 1 of this study
- Regular intake of medications or drugs potentially interfering with pain sensation (analgesics, opioids, antihistamines, calcium and potassium channel blockers, serotonin/ noradrenaline reuptake inhibitors, corticosteroids)
- Neuropathy
- Chronic pain
- Neuromuscular disease
- Dermatological disease (i.e. Atopic Dermatitis)
- Psychiatric disease
- Pregnancy / Lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Part 1: Visit 1 (No treatment) followed by Visit 2 (OLP intervention)
In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 2. Visit 1 (No treatment) will be the control of the study intervention.
|
Open-label placebo injections without any active ingredient (5 ml 0.9% saline).
All participants will be informed that the administered injections are placebo infusions.
As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP.
In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency.
The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain).
Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation.
This final current will be kept constant until the end of the particular experiment).
|
Other: Part 1: Visit 1 (OLP intervention) followed by Visit 2 (No treatment)
In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 1. Visit 2 (No treatment) will be the control of the study intervention.
|
Open-label placebo injections without any active ingredient (5 ml 0.9% saline).
All participants will be informed that the administered injections are placebo infusions.
As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP.
In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency.
The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain).
Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation.
This final current will be kept constant until the end of the particular experiment).
|
Other: Part 2/ Group A: 1x OLP (Control)
In Part 2, the Group A (Control) receives just one single OLP injection and no repetition.
|
Open-label placebo injections without any active ingredient (5 ml 0.9% saline).
All participants will be informed that the administered injections are placebo infusions.
As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP.
In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency.
The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain).
Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation.
This final current will be kept constant until the end of the particular experiment).
|
Other: Part 2/ Group B: 2x OLP; booster time fixed
In Part 2, Group B participants will receive two injections, the first at twenty minutes after start of the experiment, and the second at a time point derived from Part 1 (if data is inconclusive; at 100 minutes). For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain. |
Open-label placebo injections without any active ingredient (5 ml 0.9% saline).
All participants will be informed that the administered injections are placebo infusions.
As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP.
In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency.
The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain).
Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation.
This final current will be kept constant until the end of the particular experiment).
|
Other: Part 2/ Group C: 2x OLP; booster on- demand
In Part 2, Group C participants will receive two injections, the first at twenty minutes after start of the experiment, and the second on demand. For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain. |
Open-label placebo injections without any active ingredient (5 ml 0.9% saline).
All participants will be informed that the administered injections are placebo infusions.
As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP.
In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency.
The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain).
Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation.
This final current will be kept constant until the end of the particular experiment).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Change in Area under the Pain Curve (AUPC)
Time Frame: During three hours after administering an OLP
|
Area under the Pain Curve (AUPC) using the numeric rating scale (NRS; 0 = no pain, 10 = worst imaginable pain) during three hours after administering an OLP
|
During three hours after administering an OLP
|
Part 2: Change in Area under the Pain Curve (AUPC)
Time Frame: During three hours after administering an OLP
|
Area under the Pain Curve (AUPC) using the numeric rating scale (NRS; 0 = no pain, 10 = worst imaginable pain).
Comparison of the AUPCs of subjects receiving just one OLP injection with subjects additionally receiving one repetition of OLP administration at a time point derived from Part 1 and subjects getting the second OLP injection on-demand.
|
During three hours after administering an OLP
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and 2: Change in subjective pain ratings on each measurement point using the numeric rating scale (NRS)
Time Frame: Up to 200 minutes after electrical pain stimulation
|
Change in subjective pain ratings on each measurement point using the numeric rating scale (NRS); NRS; 0 = no pain, 10 = worst imaginable pain) every five minutes after OLP administration)
|
Up to 200 minutes after electrical pain stimulation
|
Part 1 and 2: Change in Area under the Curve (AUC) of area of hyperalgesia
Time Frame: Up to 200 minutes after electrical pain stimulation
|
Change in Area under the Curve (AUC) of area of hyperalgesia comparing the intervention and control (no treatment) visit.
Pinprick hyperalgesia will be assessed every 10 minutes after OLP administration) using a 600 millinewton (mN) von Frey filament.
|
Up to 200 minutes after electrical pain stimulation
|
Part 1 and 2: Change in Area under the Curve (AUC) of area of allodynia
Time Frame: Up to 200 minutes after electrical pain stimulation
|
Change in Area under the Curve (AUC) of area of allodynia comparing the intervention and control (no treatment) visit.
Allodynia will be determined using a dry cotton swab every 10 minutes after OLP administration).
|
Up to 200 minutes after electrical pain stimulation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tobias Schneider, MD, Department of Anaesthesiology, University Hospital of Basel (USB)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-00296; am23Schneider
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pain
-
Rajavithi HospitalCompletedTotal Abdominal Hysterectomy ,Pain , Acute Postoperative,Gabapentin , CelecoxibThailand
-
Schulthess KlinikNot yet recruiting
-
Seoul National University HospitalNot yet recruiting
-
Chung-Ang University Gwangmyeong HospitalRecruitingPostoperative Pain, AcuteKorea, Republic of
-
TC Erciyes UniversityCompletedPostoperative Pain, AcuteTurkey
-
Umraniye Education and Research HospitalNot yet recruiting
-
Sohag UniversityCompletedPostoperative Pain, AcuteEgypt
-
Northwell HealthRecruitingPain, Postoperative | Postoperative Pain, AcuteUnited States
-
Zagazig UniversityRecruiting
-
Mansoura UniversityRecruitingPostoperative Pain, AcuteEgypt
Clinical Trials on OLP-injection
-
OliPass Australia Pty LtdNovotech (Australia) Pty LimitedCompleted
-
Peking University Third HospitalRecruiting
-
InQpharm GroupCompletedDentin SensitivityGermany
-
Philipps University Marburg Medical CenterCompleted
-
Qazvin University Of Medical SciencesUnknownOral Lichen PlanusIran, Islamic Republic of
-
Philipps University Marburg Medical CenterCompleted
-
OliPass CorporationNovotech (Australia) Pty LimitedRecruiting
-
University of Alabama at BirminghamCompletedMultiple Sclerosis | FatigueUnited States
-
OliPass CorporationCompleted
-
Taipei Medical UniversityActive, not recruiting